Stock Scorer

Krystal Biotech, Inc. (KRYS)

Krystal Biotech, Inc. reported revenue of 119.2M USD for the quarter ending 30 June 2026, up 24.1% from 96M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 119.2M +24.1%
Operating Income Q2 '26 · ending 30 June 2026 58.4M +48.3%
Net Income Q2 '26 · ending 30 June 2026 54.8M +42.9%
Operating Cash Flow Q2 '26 · ending 30 June 2026 74.8M +41.8%
Free Cash Flow Q2 '26 · ending 30 June 2026 71.2M +40.1%
Shares Outstanding Q2 '26 · ending 30 June 2026 30.7M +2.6%
EPS Q2 '26 · ending 30 June 2026 7.98 +61.9%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 389.1M161.3M204.8M188.9M
20242024-12-31 290.5M65.7M89.2M119.2M
20232023-12-31 50.7M-109.6M10.9M-100.6M
20222022-12-31 0-145.2M-140M-153.5M
20212021-12-31 0-68.3M-69.6M-116.3M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30119.2M
Q1 '262026-03-31116.4M
Q4 '252025-12-31107.1M
Q3 '252025-09-3097.8M
Q2 '252025-06-3096M
Q1 '252025-03-3188.2M
Q4 '242024-12-3191.1M
Q3 '242024-09-3083.8M
Q2 '242024-06-3070.3M
Q1 '242024-03-3145.2M
Q4 '232023-12-3142.1M
Q3 '232023-09-308.6M
Q2 '232023-06-300
Q1 '232023-03-310
Q4 '222022-12-310
Q3 '222022-09-300

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-3058.4M
Q1 '262026-03-3153.7M
Q4 '252025-12-3144.3M
Q3 '252025-09-3041.4M
Q2 '252025-06-3039.4M
Q1 '252025-03-3136.3M
Q4 '242024-12-3141.4M
Q3 '242024-09-3022.5M
Q2 '242024-06-308.6M
Q1 '242024-03-31-6.7M
Q4 '232023-12-313.2M
Q3 '232023-09-30-26M
Q2 '232023-06-30-38M
Q1 '232023-03-31-48.8M
Q4 '222022-12-31-34.8M
Q3 '222022-09-30-31.5M
Q2 '222022-06-30-28.8M
Q1 '222022-03-31-50.2M
Q4 '212021-12-31-21.9M
Q3 '212021-09-30-15.7M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-3054.8M
Q1 '262026-03-3155.9M
Q4 '252025-12-3151.4M
Q3 '252025-09-3079.4M
Q2 '252025-06-3038.3M
Q1 '252025-03-3135.7M
Q4 '242024-12-3145.5M
Q3 '242024-09-3027.2M
Q2 '242024-06-3015.6M
Q1 '242024-03-31932K
Q4 '232023-12-318.7M
Q3 '232023-09-3080.7M
Q2 '232023-06-30-33.2M
Q1 '232023-03-31-45.3M
Q4 '222022-12-31-32.1M
Q3 '222022-09-30-29.9M
Q2 '222022-06-30-28.1M
Q1 '222022-03-31-50M
Q4 '212021-12-31-21.8M
Q3 '212021-09-30-15.6M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-3074.8M
Q1 '262026-03-3180.4M
Q4 '252025-12-3177.5M
Q3 '252025-09-3039.7M
Q2 '252025-06-3052.7M
Q1 '252025-03-3131M
Q4 '242024-12-3152.8M
Q3 '242024-09-3058.9M
Q2 '242024-06-30-4.2M
Q1 '242024-03-3115.9M
Q4 '232023-12-31-7.2M
Q3 '232023-09-30-21.2M
Q2 '232023-06-30-34.2M
Q1 '232023-03-31-26.2M
Q4 '222022-12-31-22.3M
Q3 '222022-09-30-19.7M
Q2 '222022-06-30-43.1M
Q1 '222022-03-31-15.5M
Q4 '212021-12-31-20.9M
Q3 '212021-09-30-7.3M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-3071.2M
Q1 '262026-03-3173.2M
Q4 '252025-12-3175.4M
Q3 '252025-09-3038M
Q2 '252025-06-3050.8M
Q1 '252025-03-3124.8M
Q4 '242024-12-3152M
Q3 '242024-09-3057.8M
Q2 '242024-06-30-5.3M
Q1 '242024-03-3114.6M
Q4 '232023-12-31-9.1M
Q3 '232023-09-30-23M
Q2 '232023-06-30-37M
Q1 '232023-03-31-31.5M
Q4 '222022-12-31-27.5M
Q3 '222022-09-30-33.7M
Q2 '222022-06-30-59.6M
Q1 '222022-03-31-32.7M
Q4 '212021-12-31-61.8M
Q3 '212021-09-30-28.2M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3030.7M
Q1 '262026-03-3130.5M
Q3 '252025-09-3029.8M
Q2 '252025-06-3029.7M
Q1 '252025-03-3129.9M
Q3 '242024-09-3029.9M
Q2 '242024-06-3029.6M
Q1 '242024-03-3129.3M
Q3 '232023-09-3028.9M
Q2 '232023-06-3026.7M
Q1 '232023-03-3125.7M
Q3 '222022-09-3025.6M
Q2 '222022-06-3025.5M
Q1 '222022-03-3125.1M
Q3 '212021-09-3022.2M
Q2 '212021-06-3022.2M
Q1 '212021-03-3121.3M
Q3 '202020-09-3019.7M
Q2 '202020-06-3018.4M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-307.98
Q1 '262026-03-317.48
Q4 '252025-12-316.85
Q3 '252025-09-306.68
Q2 '252025-06-304.93
Q1 '252025-03-314.17
Q4 '242024-12-313.00
Q3 '242024-09-302.08
Q2 '242024-06-303.96
Q1 '242024-03-312.18
Q4 '232023-12-310.39
Q3 '232023-09-30-1.47
Q2 '232023-06-30-5.43
Q1 '232023-03-31-5.28
Q4 '222022-12-31-5.51
Q3 '222022-09-30-5.21
Q2 '222022-06-30-4.74
Q1 '222022-03-31-4.38
Q4 '212021-12-31-3.13
Q3 '212021-09-30-2.71